Chinese researchers announced Saturday to have developed a vaccine for H7N9 bird flu virus, after the flu strain left over 130 people infected, of which 45 died.
According to Shu Yuelong, director of the Chinese National Influenza Centre, this is the first influenza vaccine ever developed by Chinese scientists, Xinhua reported.
The vaccine has provided important technical support to battle the new flu strain, making contribution to the H7N9 flu virus epidemic control all over the world, said Shu, also a director of the WHO Collaborating Centre for Reference and Research on Influenza.
The vaccine has been jointly developed by the First Affiliated Hospital under the School of Medicine of the Zhejiang University, Hong Kong University, Chinese Center for Disease Control and Prevention, National Institute for Food and Drug Control, and the Chinese Academy of Medical Sciences.
China reported the world's first human case for H7N9 bird flu infection in March.
As of Friday, a total of 136 people were confirmed to have been infected with the virus, according to the National Health and Family Planning Commission. Of the infected, 45 died, representing a fatality rate of about 33 percent.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
